Gilead Sciences Inc (NASDAQ:GILD)

77.79
Delayed Data
As of May 29
 +2.51 / +3.33%
Today’s Change
60.89
Today|||52-Week Range
85.97
+19.71%
Year-to-Date
Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today
May 29 / MotleyFool.com - Paid Partner Content
Before You Buy Gilead Sciences Stock, Read This
May 22 / MotleyFool.com - Paid Partner Content
Don't Waste Your Money on Penny Stocks; These 3 Are Better Buys
May 28 / MotleyFool.com - Paid Partner Content
Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results
May 21 / MotleyFool.com - Paid Partner Content
Coronavirus 2020: Where to Invest $500 Right Now
May 28 / MotleyFool.com - Paid Partner Content
How a Coronavirus Vaccine Might Move the Stock Market
May 21 / MotleyFool.com - Paid Partner Content
Here's Why Arcus Biosciences Is Losing Ground Today
May 27 / MotleyFool.com - Paid Partner Content
Why the Next Month Will Determine the Rest of the Year for Gilead's Stock
May 20 / MotleyFool.com - Paid Partner Content
Gilead Sciences Signs $2 Billion Partnership with Arcus Biosciences
May 27 / MotleyFool.com - Paid Partner Content
GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada
May 19 / MotleyFool.com - Paid Partner Content
3 Large-Cap Coronavirus Stocks Still Worth Buying
May 24 / MotleyFool.com - Paid Partner Content
Where Will Adaptimmune Be in 5 Years?
May 19 / MotleyFool.com - Paid Partner Content
Mixed Results for Gilead Sciences' COVID-19 Treatment
May 23 / MotleyFool.com - Paid Partner Content
Gilead may have a breakout coronavirus drug in remdesivir, but how do you market a pandemic treatment?
May 07 / CNN.com - Paid Partner Content
Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology?
May 23 / MotleyFool.com - Paid Partner Content